Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Charles L. Sawyers 
        • William T. Winters 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Marie-France Tschudin 
        • Lutz Hegemann 
        • Kees Roks 
        • Richard Saynor 
        • Michael Willi 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab About Novartis
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • Stories: Patients Perspectives 
      Couple holding hands Patients & Caregivers
    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor Healthcare Professionals
    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
        • Radioligand Therapy 
        • Gene Therapy 
        • Cell Therapy 
      • Research Disease Areas 
        • Immuno-oncology research at Novartis 
        • Oncology research at Novartis 
        • Cardiovascular and metabolic disease research at Novartis 
        • Autoimmunity, transplantation and inflammatory disease research at Novartis 
        • Ophthalmology research at Novartis 
        • Neuroscience Research at Novartis 
        • Musculoskeletal Disease Research at Novartis 
        • DAx: exploratory disease research at Novartis 
      • Research Locations 
        • Novartis Institute for Tropical Diseases 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research & Development Approach 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments Research & Development
    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity, Equity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda Environmental, Social and Governance
    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube Investors
    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens News
    • Careers 
      • Career Search 
      • Our Teams 
        • Careers in Commercial 
        • Careers in Communications and Engagement 
        • Careers in Consulting 
        • Careers in Digital 
        • Careers in Health, Safety & Environment 
        • Careers in Data, Digital & Information Technology (IT) 
        • Careers in Research & Development 
        • Careers in People & Organization 
        • Careers in Procurement 
        • Careers in Research 
        • Careers in Strategy 
        • Careers in Manufacturing and Supply 
        • Ethics, Risk & Compliance (ERC) 
        • Careers in Legal 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Talent 
        • US NIBR Internship Programs 
      • International Careers 
      • Personal Growth 
      • Well-being 
      A female Novartis researcher Careers
    • Clinical Trials 
      doctor taking the blood pressure of her patient Clinical Trials
    • Partnering 
      Business people working in a dark room Partnering
    • Supplier Portal 
      Group of business people in a meeting area Supplier Portal
    • Report side effects 
    • Contacts 
      Office Cubicle Contacts
    Group of scientists working in a lab in winter Home
  • Access to Healthcare
    Renewing our commitment to neglected tropical disease and malaria elimination

    Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

    Access to HealthcareClinical ResearchDrug DevelopmentInfectious DiseasesTropical Diseases
  • Access to Healthcare
    Staying one step ahead of the malaria parasite

    Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.

    Access to HealthcareInfectious DiseasesMalariaMedical InnovationsTropical Diseases
  • Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
    Basel, February 17, 2021 — Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD). The project…
    Tropical DiseasesInnovationAfricaAccess to Healthcare
  • Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
    Basel, December 9, 2019 — “We see sickle cell as a painful disease, but too often we don't translate how that pain affects the lives of our patients – can they go to school, can they work, can they enjoy their families? These are things many of us take for granted,” said Ifeyinwa Osunkwo, MD, MPH, Founder and Director, Sickle Cell Disease…
    Tropical DiseasesScientific ResearchAfrica
  • Access to Healthcare
    New drugs could offer hope for malaria patients

    In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.

    Disease EradicationGlobal Health PartnershipsMalariaNovartis Social BusinessPatient EducationTropical Diseases
  • Access to Healthcare
    Malaria fighter rides bicycle into battle with disease

    Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.

    Access to HealthcareDisease EradicationInfectious DiseasesMalariaNovartis Social BusinessTropical Diseases
  • Access to Healthcare
    A life dedicated to fighting malaria

    Lake Victoria in southwestern Kenya is on the front line in the fight against malaria, and Agnes Akoth is a key figure.

    Disease EradicationMalariaNovartis Social BusinessTropical Diseases
  • From Our Labs
    Opening chemistry education to the world

    Novartis taps MOOC technology to share chemistry education with the world

    Drug DiscoveryNovartis Institutes for BioMedical ResearchTropical DiseasesClinical ResearchBiomedical JobsEye Disorders
  • Discovery
    Killing three diseases with one stone in the lab

    Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.

    Drug DiscoveryInfectious DiseasesTropical Diseases
  • Discovery
    Experimental treatment clears malaria infections in small clinical study

    Compound offers a potential tool for fighting drug-resistant malaria parasites.

    Biomedical ResearchNovartis Social BusinessTropical Diseases

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • ESG
  • SpeakUp
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience